Aberration of the enzymatic activity of Fhit tumor suppressor protein enhances cancer cell death upon photodynamic therapy similarly to that driven by wild-type Fhit

Cancer Letters

Volumn 280, Issue 1, 2009, Pages 101-109

  Ferens, Bartosz ^a   Kawiak, Anna ^a   Banecki, Bogdan ^a   Bielawski, Krzysztof P ^a   Zawacka Pankau, Joanna ^a,b  

^a UNIVERSITY OF GDA SK   (Poland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Complex detection; Fhit; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; HISTIDINE; PROTOPORPHYRIN;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ACID ANHYDRIDE HYDROLASES; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; HELA CELLS; HUMANS; HYDROLYSIS; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEINS;

EID: 67349172848     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.014     Document Type: Article

References (29)

1. Barnes L.D., Garrison P.N., Siprashvili Z., Robinson A.K., Ingram S.W., Croce C.M., Ohta M., and Huebner K. Fhit, a putative tumor suppressor in humans is a dinucleoside 5′,5′′′-P1, P3-triphosphate hydrolase. Biochemistry 35 (1996) 11529-11535
2. McLennan A.G. Dinucleoside polyphosphates - friend or foe?. Pharmacol. Ther. 87 (2000) 73-89
3. Campiglio M., Bianchi F., Andriani F., Sozzi G., Tagliabue E., Menard S., and Roz L. Diadenosines as FHIT-ness instructors. J. Cell. Physiol. 208 (2006) 274-281
4. Pace H.C., Garrison P.N., Robinson A.K., Barnes L.D., Draganescu A., Rösler A., Blackburn G.M., Siprashvili Z., Croce C.M., Huebner K., and Brenner C. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc. Natl. Acad. Sci. USA 95 (1998) 5484-5489
5. Brenner C., Bieganowski P., Pace H.C., and Huebner K. The histidine triad superfamily of nucleotide-binding proteins. J. Cell. Physiol. 181 (1999) 179-187
6. Pace H.C., Hodawadekar S.C., Draganescu A., Huang J., Bieganowski P., Pekarsky Y., Crocer C.M., and Brenner C. Crystal structure of the worm NitFhit Rosetta stone protein reveals a Nit tetramer binding two Fhit dimers. Curr. Biol. 10 (2000) 907-917
7. Ishii H., Mimori K., Inoue H., Inageta T., Ishikawa K., Semba S., Druck T., Trapasso F., Tani K., Vecchione A., Croce C.M., Mori M., and Huebner K. Fhit modulates the DNA damage checkpoint response. Cancer Res. 66 (2006) 11287-11292
8. Huebner K., and Croce C.M. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br. J. Cancer 88 10 (2003) 1501-1506
9. Fong L.Y., Fidanza V., Zanesi N., Lock L., Siracusa L., Mancini R., Siprashvili Z., Ottey M., Martin S.E., Druck T., McCue P.A., Croce C.M., and Huebner K. Muir-Torre-like syndrome in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 97 9 (2000) 4742-4747
10. Zanesi N., Fidanza V., Fong L.Y., Mancini R., Druck T., Valtieri M., Rudiger T., McCue P.A., Croce C.M., and Huebner K. The tumor spectrum in FHIT-deficient mice. Proc. Natl. Acad. Sci. USA 98 18 (2001) 10250-10255
11. Dumon K.R., Ishii H., Fong L.Y., Zanesi N., Fidanza V., Mancini R., Vecchione A., Baffa R., Trapasso F., During M.J., Huebner K., and M Croce C. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 98 6 (2001) 3346-3351
12. Ishii H., Zanesi N., Vecchione A., Trapasso F., Yendamuri S., Sarti M., Baffa R., During M.J., Huebner K., Fong L.Y., and Croce C.M. Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J. 17 12 (2003) 1768-1770
13. Siprashvili Z., Sozzi G., Barnes L.D., McCue P., Robinson A.K., Eryomin V., Sard L., Tagliabue E., Greco A., Fusetti L., Schwartz G., Pierotti M.A., Croce C.M., and Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA 94 (1997) 13771-13776
14. Ji L., Fang B., Yen N., Fong K., Minna J.D., and Roth J.A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59 (1999) 3333-3339
15. Ishii H., Dumon K.R., Vecchione A., Trapasso F., Mimori K., Alder H., Mori M., Sozzi G., Baffa R., Huebner K., and Croce C.M. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res. 61 4 (2001) 1578-1584
16. Roz L., Gramegna M., Ishii H., Croce C.M., and Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc. Natl. Acad. Sci. USA 99 (2002) 3615-3620
17. Trapasso F., Krakowiak A., Cesari R., Arkles J., Yendamuri S., Ishii H., Vecchione A., Kuroki T., Bieganowski P., Pace H.C., Huebner K., Croce C.M., and Brenner C. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc. Natl. Acad. Sci. USA 100 4 (2003) 1592-1597
18. Trapasso F., Pichiorri F., Gaspari M., Palumbo T., Aqeilan R.I., Gaudio E., Okumura H., Iuliano R., Di Leva G., Fabbri M., Birk D.E., Raso C., Green-Church K., Spagnoli L.G., Venuta S., Huebner K., and Croce C.M. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J. Biol. Chem. 283 20 (2008) 13736-13744
19. Zawacka-Pankau J., Kowalska A., Issaeva N., Burcza A., Kwiek P., Bednarz N., Pramanik A., Banecki B., and Podhajska A.J. Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy. J. Photochem. Photobiol. B 86 1 (2007) 35-42
20. Zawacka-Pankau J., Krachulec J., Grulkowski I., Bielawski K.P., and Selivanova G. The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. Toxicol. Appl. Pharmacol. (2008) 10.1016/j.taap.2008.07.012
21. Zawacka-Pankau J., Issaeva N., Hossain S., Pramanik A., Selivanova G., and Podhajska A.J. Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner. J. Biol. Chem. 282 4 (2007) 2466-2472
22. Zawacka-Pankau J., and Podhajska A.J. Expression and simple, one-step purification of fragile histidine triad (Fhit) tumor suppressor mutant forms in Escherichia coli and their interaction with protoporphyrin IX. Biotechnol. Lett. 29 6 (2007) 877-883
23. Kowalska A., Kwiek P., Miłosz E., Gondek G., Romiszewska A., Graczyk A., and Podhajska A.J. Application of electrophoretic methods for detection of protein-porphyrin complexes. Acta Biochim. Pol. 50 4 (2003) 1155-1163
24. Kawiak A., Piosik J., Stasilojc G., Bigda J.J., and Lojkowska E. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol. Appl. Pharmacol. 223 3 (2007) 267-276
25. Fisher D.I., and McLennan A.G. Correlation of intracellular diadenosine triphosphate (Ap3A) with apoptosis in Fhit-positive HEK293 cells. Cancer Lett. 259 2 (2008) 86-191
26. Golebiowski F., Szulc A., Szutowicz A., and Pawelczyk T. Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch. Biochem. Biophys. 428 (2004) 160-164
27. Shi Y., Zou M., Fraid N.R., and Paterson M.C. Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem. J. 352 (2000) 443-448
28. Pekarsky Y., Garrison P.N., Palamarchuk A., Zanesi N., Aqeilan R.I., Huebner K., Barnes L.D., and Croce C.M. Fhit is a physiological target of the protein kinase Src. Proc. Natl. Acad. Sci. USA 11 (2004) 3775-3779
29. Bianchi F., Magnifico A., Olgiati C., Zanesi N., Pekarsky Y., Tagliabue E., Croce C.M., Ménard S., and Campiglio M. Fhit proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc. Natl. Acad. Sci. USA 103 50 (2006) 18981-18986